When did Emergent Biosolutions report Q2 2025 earnings?

Emergent Biosolutions (EBS) reported Q2 2025 earnings on August 6, 2025 after market close.

What were Emergent Biosolutions's Q2 2025 revenue and EPS?

Emergent Biosolutions reported revenue of $140.9M and eps of $0.16 for Q2 2025.

Did Emergent Biosolutions beat estimates in Q2 2025?

Revenue missed the consensus estimate of $203.7M by $62.8M. EPS beat the consensus estimate of $-0.26 by $0.42.

How did Emergent Biosolutions's Q2 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue declined 44.7% from $254.7M a year earlier.

Where can I find Emergent Biosolutions's Q2 2025 SEC filings?

You can read the 10-Q periodic report (0001367644-25-000181) directly on SEC EDGAR. The filing index links above go to sec.gov.

Emergent Biosolutions EBS Q2 2025 earnings

Reported August 6, 2025 · After market close

Revenue$140.9MMiss by $62.8M

EPS$0.16Beat by $0.42

Revenue estimate$203.7M

EPS estimate-$0.26

Next report

Aug 5, 2026 (In 6 days)

Revenue estimate$177.5M

EPS estimate-$0.09

Financials

Q2 2025

Income statement

See full

Revenue$140.9M-44.7%

Gross profit$74.0M+279%

Operating income$1.6M+101%

Net income-$12.0M+95.8%

EPS (diluted)-$0.22+95.9%

Balance sheet

See full

Cash & equivalents$271.0M+282%

Total debt$676.1M-22.9%

Total equity$536.2M+38.8%

Total assets$1.4B-6.4%

Cash flow

See full

Operating cash flow$106.4M—

CapEx$2.9M-37.0%

Free cash flow$103.5M—

Valuation & ratios

Valuation

as of 06/30/25

See full

Market cap$367.46M+2.8%

Enterprise value$772.56M-33.6%

P/E2.6×—

P/S0.4×+0.1×

Profitability

See full

Gross margin53.5%+26.3pp

Operating margin12.5%+7.1pp

Net margin16.4%+9.3pp

Returns & leverage

See full

Return on equity30.2%+17.4pp

Debt / equity1.3×-1.0×

Current ratio5.7×+4.6×

Segments

By product

See full

Commercial Product sales$67.5M-43.8%

MCM Product sales$58.4M-7.9%

All other revenue$15.0M—

By segment

See full

MCM Products$58.4M-7.9%

By geography

See full

Canada$18.8M—

Versus estimates

Revenue

Q1 2026$156.1MBeat by $11.1M Q4 2025$148.7MMiss by $68.8M Q3 2025$231.1MBeat by $13.6M

Q2 2025$140.9MMiss by $62.8M

Q1 2025$222.2MBeat by $3.2M Q4 2024$189.3MMiss by $89.7M

Diluted EPS

Q1 2026$0.21Beat by $0.46 Q4 2025-$0.43Miss by $0.54 Q3 2025$1.06Beat by $1.18

Q2 2025$0.16Beat by $0.42

Q1 2025$0.71Beat by $0.22 Q4 2024$0.05Beat by $0.40

Ask the moment Emergent Biosolutions reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Emergent Biosolutions report Q2 2025 earnings?: Emergent Biosolutions (EBS) reported Q2 2025 earnings on August 6, 2025 after market close.
What were Emergent Biosolutions's Q2 2025 revenue and EPS?: Emergent Biosolutions reported revenue of $140.9M and eps of $0.16 for Q2 2025.
Did Emergent Biosolutions beat estimates in Q2 2025?: Revenue missed the consensus estimate of $203.7M by $62.8M. EPS beat the consensus estimate of $-0.26 by $0.42.
How did Emergent Biosolutions's Q2 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue declined 44.7% from $254.7M a year earlier.
Where can I find Emergent Biosolutions's Q2 2025 SEC filings?: You can read the 10-Q periodic report (0001367644-25-000181) directly on SEC EDGAR. The filing index links above go to sec.gov.